Galderma's CEO Flemming Ørnskov revealed that the rising use of GLP-1 weight-loss medications like Ozempic and Wegovy is driving strong growth in the company's aesthetics portfolio, including fillers and anti-wrinkle treatments. About 10% of U.S. adults now use these drugs, creating demand for products that address facial sagging linked to significant weight loss, a condition sometimes called "Ozempic face." Galderma reported nearly 25% sales growth year-on-year at constant currencies, with U.S. sales growing 32%, outpacing other regions. This trend presents a significant but early-stage opportunity for the company in the aesthetics market.
The global battery graphite market, valued at $9.20 billion in 2025, is forecasted to grow at a 9.5% CAGR to $25.77 billion by 2036. This growth is fueled by rising lithium-ion battery production for electric vehicles and energy storage systems, alon...
amaran has introduced the Cam 4K webcam, designed to enhance video streaming by automatically adjusting lighting when paired with amaran light fixtures. This webcam features superfast autofocus, 2x lossless 4K zoom, and up to 72 hours of runtime, mak...
The global GPU accelerator card market is projected to grow from $29.18 billion in 2025 to $74.86 billion by 2031, driven by rapid advances in AI, machine learning, cloud gaming, and high-performance computing. Increasing AI model sizes and computati...
The HVAC filters market is projected to grow from USD 4.66 billion in 2026 to USD 6.21 billion by 2031, at a CAGR of 5.9%. This growth is fueled by increasing awareness of indoor air quality, stricter regulations, and expanding infrastructure in cons...
In Q3 2026, vehicle sales remained steady but inventory levels increased by 9%, with a significant portion of both new and used vehicles aging on dealer lots. New vehicle inventory prices rose faster than sale prices, risking margin losses through ma...
